Evidence map›Paper›PMID 26284486›Full record

ArticleOncotarget2015

Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients.

Rui Shi, Pei-Yin Wang, Xin-Yi Li, Jian-Xin Chen, Yan Li, Xin-Zhong Zhang, Chen-Guang Zhang, Tao Jiang, Wen-Bin Li, Wei Ding and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 5 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 5 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Rui ShiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Pei-Yin WangDepartment of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Henan, China.
Xin-Yi LiUniversity of South Florida, Tampa, FL, USA.
Jian-Xin ChenDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yan LiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Xin-Zhong ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Henan, China.
Chen-Guang ZhangBeijing Key Laboratory for Tumor Invasion and Metastasis, Cancer Institute of Capital Medical University, Beijing, China.
Tao JiangDepartment of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China.
Wen-Bin LiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wei DingBeijing Key Laboratory for Tumor Invasion and Metastasis, Cancer Institute of Capital Medical University, Beijing, China.
Shu-Jun ChengDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Beijing Shijitan Hospital · CNCapital Medical University · CNFirst Affiliated Hospital of Xinxiang Medical University · CNUniversity of South Florida · USXinxiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is a most common type of primary brain tumors. Extracellular vesicles, in the form of exosomes, are known to mediate cell-cell communication by transporting cell-derived proteins and nucleic acids, including various microRNAs (miRNAs). Here we examined the cerebrospinal fluid (CSF) from patients with recurrent glioma for the levels of cancer-related miRNAs, and evaluated the values for prognosis by comparing the measures of CSF-, serum-, and exosome-contained miR-21 levels. Samples from seventy glioma patients following surgery were compared with those from brain trauma patients as a non-tumor control group. Exosomal miR-21 levels in the CSF of glioma patients were found significantly higher than in the controls; whereas no difference was detected in serum-derived exosomal miR-21 expression. The CSF-derived exosomal miR-21 levels correlated with tumor spinal/ventricle metastasis and the recurrence with anatomical site preference. From additional 198 glioma tissue samples, we verified that miR-21 levels associated with tumor grade of diagnosis and negatively correlated with the median values of patient overall survival time. We further used a lentiviral inhibitor to suppress miR-21 expression in U251 cells. The results showed that the levels of miR-21 target genes of PTEN, RECK and PDCD4 were up-regulated at protein levels. Therefore, we concluded that the exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis.

Indexed as

AdultAgedApoptosis Regulatory ProteinsAstrocytomaBiomarkers, TumorBrain NeoplasmsCell Line, TumorDisease ProgressionEpendymomaExosomesFemaleGene Expression Regulation, NeoplasticGlioblastomaGliomaGPI-Linked ProteinsHumansApoptosis Regulatory ProteinsBiomarkers, TumorGPI-Linked ProteinsMicroRNAsMIRN21 microRNA, humanPDCD4 protein, humanPTEN PhosphohydrolasePTEN protein, humanRECK protein, humanRNA-Binding Proteinscancer prognosiscerebrospinal fluidextracellular vesiclesgliomahsa-miR-21

Identifiers

PMID26284486
PMCPMC4694967
OpenAlexW2107705644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.